ChartPull helps organizations connect to real-time EMR data instantly.
Learn More

A.M. Beajow, M.D. Internal Medicine Associates ACO, P.C

ACO Details

ACO Service Area(s):  NV 

A.M. Beajow, M.D. Internal Medicine Associates ACO, P.C

1175 American Pacific Dr., Ste. FLas VegasNevada 89074 

Executive Contact

Dr. Mahfoud Beajow
Request Contact Details

Public Contact

Howard Jones
(702) 792-4336
tripp@hc360usa.com
Overview

A.M. Beajow, M.D. Internal Medicine Associates ACO, P.C was started in January 2013. In its first year, this organization spent $67,555,873 total on its 5,921 individual beneficiaries (including beneficiaries only in the ACO for a partial year). By comparison, in its benchmark year, it spent $70,912,015 per beneficiary, a difference of $3,356,142. The ACO successfully reported, having earned its participants $1,678,071.

This is a Track 1 Shared Savings ACO which means it has accepted only upside with no downside risk in exchange for a smaller maximum shared savings rate. If the ACO spends less than 3.62% per-beneficiary compared to the benchmark years, the participants will be paid 50% of the savings.

ACOs can request early payments to help finance the startup costs of the ACO. This ACO did not accept any advanced payments.

The 5,921 individual beneficiaries spent a total 5,766 person-years in the ACO. Partial years are frequently due to things such as new medicare members entering the ACO and death.

2013 Performance

Earned Savings

$1,644,510

Cost Reduction

4.7%

Quality Points

32.05 of 581

Medicare Shared Savings Program Quality Measures
All 33 measures must be reported to CMS but not all are used to calculate the performance.
More Information
DescriptionMeasuresPercentile
Patient/Caregiver Experience
 Getting Timely Care, Appointments, and Information ACO-1 
 
 
 
 
 
 
 
70-80th
 How Well Your Doctors Communicate ACO-2 
 
 
 
 
 
 
 
Above 90th
 Patients' Rating of Doctor ACO-3 
 
 
 
 
 
 
 
Above 90th
 Access to Specialists ACO-4 
 
 
 
 
 
 
 
80-90th
 Health Promotion and Education ACO-5 
 
 
 
 
 
 
 
60-70th
 Shared Decision Making ACO-6 
 
 
 
 
 
 
 
80-90th
 Health Status/Functional Status ACO-7 
 
 
 
 
 
 
 
Above 90th
Care Coordination/Patient Safety
 Risk Standardized, All Condition Readmissions ACO-8 
 
 
 
 
 
 
 
Above 90th
 ASC Admissions: COPD or Asthma in Older Adults ACO-9 
 
 
 
 
 
 
 
70-80th
 ASC Admission: Heart Failure ACO-10 
 
 
 
 
 
 
 
40-50th
 Percent of PCPs who Qualified for EHR Incentive Payment ACO-11 
 
 
 
 
 
 
 
60-70th
 Medication Reconciliation ACO-12 
 
 
 
 
 
 
 
70-80th
 Falls: Screening for Fall Risk ACO-13 
 
 
 
 
 
 
 
Below 30th
Preventive Health
 Influenza Immunization ACO-14 
 
 
 
 
 
 
 
Below 30th
 Pneumococcal Vaccination ACO-15 
 
 
 
 
 
 
 
Below 30th
 Adult Weight Screening and Follow-up ACO-16 
 
 
 
 
 
 
 
Below 30th
 Tobacco Use Assessment and Cessation Intervention ACO-17 
 
 
 
 
 
 
 
60-70th
 Depression Screening ACO-18 
 
 
 
 
 
 
 
Below 30th
 Colorectal Cancer Screening ACO-19 
 
 
 
 
 
 
 
40-50th
 Mammography Screening ACO-20 
 
 
 
 
 
 
 
30-40th
 Proportion of Adults who had blood pressure screened in past 2 years ACO-21 
 
 
 
 
 
 
 
70-80th
At-Risk Population Diabetes
 Patients who meet all the following measures
Low Density Lipoprotein (LDL) (<100 mg/dL), Aspirin Use, Hemoglobin A1c Control (HbA1c) (<8 percent), Blood Pressure (BP) < 140/90, Tobacco Non Use
ACO-23 ACO-26 ACO-22 ACO-24 ACO-25 
 
 
 
 
 
 
 
30-40th
 Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent) ACO-27 
 
 
 
 
 
 
 
60-70th
At-Risk Population Hypertension
 Percent of beneficiaries with hypertension whose BP < 140/90 ACO-28 
 
 
 
 
 
 
 
30-40th
At-Risk Population IVD
 Percent of beneficiaries with IVD with complete lipid profile and LDL control < 100mg/dl ACO-29 
 
 
 
 
 
 
 
Below 30th
 Percent of beneficiaries with IVD who use Aspirin or other antithrombotic ACO-30 
 
 
 
 
 
 
 
Below 30th
At-Risk Population HF
 Beta-Blocker Therapy for LVSD ACO-31 
 
 
 
 
 
 
 
Below 30th
At-Risk Population CAD
 Patients who meet all the following measures
Drug Therapy for Lowering LDL Cholesterol, ACE Inhibitor or ARB Therapy for Patients with CAD and Diabetes and/or LVSD
ACO-32 ACO-33 
 
 
 
 
 
 
 
Below 30th
ACO Statistics